Atlanta, Georgia — September 8, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chief Medical Officer and clinical collaborators will present data highlighting the cross-variant antibody and robust cellular immune responses induced by the Company’s next-generation COVID-19 vaccine (GEO-CM04S1) in immunocompromised patients with hematologic malignancies at two upcoming scientific meetings in September.
The 6th ESCMID Conference on Vaccines will take place September 10-13, 2025, in Lisbon, Portugal, where Kelly T. McKee, Jr., MD, MPH, Chief Medical Officer, GeoVax Labs, Atlanta, Georgia, will present a poster (P060) on GEO-CM04S1. The International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) will take place September 12–15, 2025, in Krakow, Poland, where Alexey V. Danilov, MD, PhD, Professor, Department of Hematology and Transplantation; City of Hope National Medical Center, Duarte, California, will present a poster (1717) on MVA-based GEO-CM04S1 vaccine results.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products.
Contact: Jessica Starman, media@geovax.com
Source: GeoVax Labs, Inc.
